Diabetes: Page 2
-
Courtesy of Tandem Diabetes Care
Q&ATandem CMO shares Mobi feedback, expansion plans
MedTech Dive caught up with Chief Medical Officer Jordan Pinsker to talk about early feedback on Tandem’s smallest insulin pump and what’s next for the device.
By Elise Reuter • July 29, 2024 -
Permission granted by Dexcom
Dexcom shares plunge on lower sales outlook
“I’m just kind of in shock,” an analyst said on the earnings call, asking for more detail on the forecast cut.
By Elise Reuter • July 26, 2024 -
Permission granted by Abbott Laboratories
Abbott recalls Freestyle Libre 3 sensors due to incorrect glucose readings
A spokesperson for Abbott said the recall “may impact less than 1% of Libre 3 users in the U.S.”
By Nick Paul Taylor • July 26, 2024 -
Permission granted by Nasdaq
Diabetes device firm Embecta considers sale: Financial Times
Two years after Embecta spun out of BD, the firm is now exploring a potential sale, the Financial Times reported.
By Elise Reuter • July 22, 2024 -
Permission granted by Abbott
Abbott previews PFA, over-the-counter CGM markets
Electrophysiology sales held up against rivals’ launches of pulsed field ablation systems. Meanwhile, Abbott is gauging sales of its first OTC CGMs.
By Elise Reuter • July 18, 2024 -
Courtesy of Intuitive Surgical
J&J, Abbott and Intuitive start medtech earnings season
The companies’ financial results will offer a glimpse at the current health of medtech markets.
By Nick Paul Taylor • July 16, 2024 -
iStock via Getty Images
Roche wins CE mark for its first CGM
The clearance positions Roche to challenge Abbott and Dexcom for the European continuous glucose monitor market.
By Nick Paul Taylor • Updated July 10, 2024 -
Courtesy of Dexcom
Abbott and Dexcom are launching the first over-the-counter CGMs. Here are 7 questions on the new tech.
Experts expect the release of new over-the-counter glucose monitors in the U.S. to fuel more widespread use of the devices.
By Elise Reuter • June 26, 2024 -
Permission granted by Embecta
Embecta touts its insulin patch pump at ADA
Embecta said its device, with a larger insulin reservoir, addresses an unmet need for people with Type 2 diabetes.
By Elise Reuter • June 25, 2024 -
Retrieved from Ascensia Diabetes Care on June 25, 2024
Senseonics tips 365-day CGM to double 2025 sales
Senseonics is in talks with insulin pump manufacturers about integrating its implantable Eversense continuous glucose monitor with their devices.
By Nick Paul Taylor • June 25, 2024 -
Courtesy of Insulet Corp.
Insulet seeks label expansion of Omnipod 5 for Type 2 diabetes
At the American Diabetes Association meeting, Insulet shared study results showing improvements in blood glucose and quality of life.
By Elise Reuter • June 24, 2024 -
Courtesy of Tandem Diabetes Care
Tandem names Jean-Claude Kyrillos as chief operating officer
The appointment gives Kyrillos a leading role in work to expand the insulin delivery company’s global operations and achieve profitable growth.
By Nick Paul Taylor • June 21, 2024 -
Permission granted by Abbott
Abbott ramps up over-the-counter CGM race with new sensors
Abbott will launch two over-the-counter glucose monitors in the U.S., competing directly with Dexcom’s Stelo.
By Elise Reuter • June 10, 2024 -
Retrieved from Dexcom on June 05, 2024
Dexcom connects G7 CGM directly to Apple Watch in US
Apple Watch and G7 users can now view real-time glucose readings on their wrist, regardless of whether they are carrying an iPhone.
By Nick Paul Taylor • Updated June 7, 2024 -
Ethan Miller via Getty Images
Abbott receives FDA OK for over-the-counter glucose monitor
After debuting its Lingo device in the U.K. last year, Abbott can now sell the sensor in the U.S.
By Elise Reuter • June 3, 2024 -
Courtesy of Tandem Diabetes Care
Medicare adviser sets recommendations for diabetes device evidence
A MEDCAC panel found time in range was an “extremely important” metric, but members were divided on whether quality of life measures should influence coverage.
By Elise Reuter • May 22, 2024 -
Courtesy of Dexcom
Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage
Diabetes tech companies shared updates on new products, largely focused on Type 2 patients, in Q1 earnings calls.
By Elise Reuter • May 16, 2024 -
deberarr via Getty Images
FDA targets health inequality by improving at-home devices
Michelle Tarver, an FDA official, said a new program is meant to advance health equity by considering people’s living conditions as part of medical device design.
By Elise Reuter • May 13, 2024 -
Courtesy of Tandem Diabetes Care
Tandem reports 224 injuries related to faulty insulin pump app
A problem with Tandem’s iPhone app could drain the battery of the connected insulin pump, causing it to power down sooner than expected.
By Nick Paul Taylor • May 9, 2024 -
Permission granted by Senseonics
Senseonics gets FDA clearance to pair CGM implant with insulin pumps
Analysts said the designation and planned one-year sensor could help Senseonics’ device appeal to more patients.
By Nick Paul Taylor • May 1, 2024 -
Courtesy of Boston Scientific
Boston Scientific, Dexcom and Edwards next as earnings season rolls on
J.P. Morgan analysts expect this week’s results to be “very good” following reports from J&J, Abbott and Intuitive Surgical.
By Nick Paul Taylor • April 23, 2024 -
Courtesy of Insulet Corp.
Insulet names Ana Maria Chadwick CFO
Chadwick succeeds Wayde McMillan, who left last year to become CFO for 3M’s health spinoff.
By Nick Paul Taylor • March 21, 2024 -
Courtesy of Sequel Med Tech
Deka’s automated insulin delivery system, powered by patient-led app, gets FDA clearance
Sequel Med Tech will sell the new system, which integrates with Tidepool’s Loop insulin dosing algorithm.
By Nick Paul Taylor • March 20, 2024 -
Getty Images via Getty Images
Better Therapeutics lays off staff, considers winding down business
The digital therapeutics developer received authorization for a Type 2 diabetes treatment app last year but has struggled for money.
By Nick Paul Taylor • March 15, 2024 -
Courtesy of Dexcom
Dexcom’s over-the-counter nod sets stage for broader CGM use
The FDA’s decision allows people who don’t take insulin, including those who don’t have diabetes, to use the devices without a prescription.
By Elise Reuter • March 7, 2024
Previous
